MedTrace Logo

Antiischemic Effects of Empagliflozin in Diabetic Patients With Refractory Angina

NCT04143321 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2019-10-29

No results posted yet for this study

Summary

this study was aimed to evaluation of antiangial effect of a new fda drug approval on angina in diabetic patient with refractory angina

Conditions

Interventions

DRUG

Empagliflozin 25 MG

after washout period and EST and SAQ patients gave 25 mg Empagliflozin daily in experimental group

Sponsors & Collaborators

  • Isfahan University of Medical Sciences

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-10
Primary Completion
2019-04-15
Completion
2019-05-23

Countries

  • Iran

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04143321 on ClinicalTrials.gov